Jim Simons Prelude Therapeutics Inc Transaction History

Renaissance Technologies LLC

$63.1 Billion
Q3 2024

A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Prelude Therapeutics Inc stock. As of the latest transaction made, Renaissance Technologies LLC holds 196,900 shares of PRLD stock, worth $255,970. This represents 0.0% of its overall portfolio holdings.

Number of Shares

196,900

Previous 206,600 4.7%

Holding current value

$255,970

Previous $787,000 48.28%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$2.07 - $6.37 $20,079 - $61,789	-9,700 Reduced 4.7%	196,900 $407,000
Q2 2024 Aug 09, 2024	SELL	$3.32 - $5.63 $126,824 - $215,066	-38,200 Reduced 15.6%	206,600 $787,000
Q1 2024 May 13, 2024	BUY	$2.68 - $4.84 $76,112 - $137,456	28,400 Added 13.12%	244,800 $1.16 Million
Q4 2023 Feb 13, 2024	BUY	$1.69 - $4.37 $130,173 - $336,603	77,026 Added 55.27%	216,400 $924,000
Q3 2023 Nov 14, 2023	SELL	$2.74 - $4.79 $120,357 - $210,405	-43,926 Reduced 23.96%	139,374 $431,000
Q2 2023 Aug 11, 2023	BUY	$4.45 - $8.12 $199,360 - $363,775	44,800 Added 32.35%	183,300 $825,000
Q1 2023 May 12, 2023	BUY	$4.58 - $7.34 $9,160 - $14,680	2,000 Added 1.47%	138,500 $789,000
Q4 2022 Feb 13, 2023	SELL	$4.61 - $8.5 $31,809 - $58,650	-6,900 Reduced 4.81%	136,500 $824,000
Q3 2022 Nov 14, 2022	SELL	$5.0 - $8.82 $85,430 - $150,698	-17,086 Reduced 10.65%	143,400 $948,000
Q2 2022 Aug 12, 2022	BUY	$4.0 - $7.55 $481,544 - $908,914	120,386 Added 300.21%	160,486 $838,000
Q1 2022 May 13, 2022	SELL	$6.9 - $13.22 $600,990 - $1.15 Million	-87,100 Reduced 68.47%	40,100 $277,000
Q4 2021 Feb 11, 2022	BUY	$11.89 - $31.74 $1.51 Million - $4.04 Million	127,200 New	127,200 $1.58 Million

Others Institutions Holding PRLD

# of Institutions

Shares Held

35.7M

Call Options Held

500

Put Options Held

300

View Full List

About Prelude Therapeutics Inc

Ticker PRLD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,369,200
Market Cap $47.3M
Description
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid ...

More about PRLD

Track Jim Simons's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.

Account